logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

Jan 23, 2024•almost 2 years ago

Acquiring Company

NAYA Biosciences

Acquired Company

Florida Biotechnologies

AventuraTampaBiotechnologyHealth CareGeneticsTherapeutics

Description

NAYA Biosciences Inc. has entered into a binding letter of intent to acquire Florida Biotechnologies, Inc., a gene therapy company focusing on the treatment of mitochondrial diseases. The acquisition is aimed at accelerating clinical development and early patient access to a breakthrough AAV gene therapy platform for mitochondrial genetic diseases, particularly targeting LHON.

Company Information

Company

NAYA Biosciences

Location

Aventura, Florida, United States

About

NAYA Biosciences is building a group of companies leveraging the next generation of biotechnologies to increase patient access to life-transforming treatments in oncology, fertility, and regenerative medicine. Our unique capabilities in biology, cell and gene therapy, and artificial intelligence provide a synergistic platform for the accelerated clinical development and commercialization of these breakthrough treatments.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed